FIGURE 6.

Protective effects of depolymerase and phage in mice challenged with wild-type P. multocida strain HB03. (A) Treatment efficacy of purified recombinant depolymerase. (B) Treatment efficacy of phage PHB02. (C) Clinical symptom scores post-challenge with purified recombinant depolymerase. (D) Clinical symptom scores post-challenge with phage PHB02. Treatment groups were as follows: a, infected with P. multocida strain HB03; b, phage treatment 6 h post-infection; c, phage treatment 12 h post-infection; d, multiple-dose phage treatment 12 h post-infection; e, Dep-ORF8 treatment 6 h post-infection; f, Dep-ORF8 treatment 12 h post-infection; g, multiple-dose Dep-ORF8 treatment 12 h post-infection; h, inoculated with PBS only. The total score for the health status of each group was recorded at least three times per day. The data are expressed as the mean ± SD.